News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Singulair Prescriptions Plunge After Generics Arrived


9/12/2012 7:15:54 AM

Weekly prescriptions for Merck & Co.'s asthma and allergy treatment Singulair plunged nearly 90% within four weeks of the August introduction of competing generic copies, a Merck executive said Tuesday. "There's been a rapid decline and loss of sales," Adam H. Schechter, president of Merck's global human-health unit, told investors at a Morgan Stanley health-care conference in New York. Weekly prescriptions for branded Singulair declined 87% four weeks after the early August loss of U.S. patent protection for the drug, according to a slide presented by Mr. Schechter. The patent loss triggered the introduction of lower-priced, generic versions of the drug from multiple manufacturers including Mylan Inc. and Endo Health Solutions.

Read at Market Watch
Read at Seeking Alpha
Read at Nasdaq


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES